246 related articles for article (PubMed ID: 22392565)
1. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
[TBL] [Abstract][Full Text] [Related]
2. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
Gamis AS; Woods WG; Alonzo TA; Buxton A; Lange B; Barnard DR; Gold S; Smith FO;
J Clin Oncol; 2003 Sep; 21(18):3415-22. PubMed ID: 12885836
[TBL] [Abstract][Full Text] [Related]
3. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.
Woods WG; Kobrinsky N; Buckley JD; Lee JW; Sanders J; Neudorf S; Gold S; Barnard DR; DeSwarte J; Dusenbery K; Kalousek D; Arthur DC; Lange BJ
Blood; 1996 Jun; 87(12):4979-89. PubMed ID: 8652810
[TBL] [Abstract][Full Text] [Related]
4. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
Taub JW; Berman JN; Hitzler JK; Sorrell AD; Lacayo NJ; Mast K; Head D; Raimondi S; Hirsch B; Ge Y; Gerbing RB; Wang YC; Alonzo TA; Campana D; Coustan-Smith E; Mathew P; Gamis AS
Blood; 2017 Jun; 129(25):3304-3313. PubMed ID: 28389462
[TBL] [Abstract][Full Text] [Related]
5. Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.
Lange BJ; Dinndorf P; Smith FO; Arndt C; Barnard D; Feig S; Feusner J; Seibel N; Weiman M; Aplenc R; Gerbing R; Alonzo TA
J Clin Oncol; 2004 Jan; 22(1):150-6. PubMed ID: 14701777
[TBL] [Abstract][Full Text] [Related]
6. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498.
Ravindranath Y; Abella E; Krischer JP; Wiley J; Inoue S; Harris M; Chauvenet A; Alvarado CS; Dubowy R; Ritchey AK
Blood; 1992 Nov; 80(9):2210-4. PubMed ID: 1384797
[TBL] [Abstract][Full Text] [Related]
7. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
[TBL] [Abstract][Full Text] [Related]
8. Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study.
Rytting M; Ravandi F; Estey E; Cortes J; Faderl S; Garcia-Manero G; Jeha S; Ouzounian S; Pierce S; Kantarjian H
Cancer; 2010 Nov; 116(22):5272-8. PubMed ID: 20665501
[TBL] [Abstract][Full Text] [Related]
9. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
[TBL] [Abstract][Full Text] [Related]
11. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG
J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034
[TBL] [Abstract][Full Text] [Related]
12. Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.
Taga T; Watanabe T; Tomizawa D; Kudo K; Terui K; Moritake H; Kinoshita A; Iwamoto S; Nakayama H; Takahashi H; Shimada A; Taki T; Toki T; Ito E; Goto H; Koh K; Saito AM; Horibe K; Nakahata T; Tawa A; Adachi S
Pediatr Blood Cancer; 2016 Feb; 63(2):248-54. PubMed ID: 26481183
[TBL] [Abstract][Full Text] [Related]
13. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Rao A; Hills RK; Stiller C; Gibson BE; de Graaf SS; Hann IM; O'Marcaigh A; Wheatley K; Webb DK
Br J Haematol; 2006 Mar; 132(5):576-83. PubMed ID: 16445830
[TBL] [Abstract][Full Text] [Related]
14. Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial.
Uffmann M; Rasche M; Zimmermann M; von Neuhoff C; Creutzig U; Dworzak M; Scheffers L; Hasle H; Zwaan CM; Reinhardt D; Klusmann JH
Blood; 2017 Jun; 129(25):3314-3321. PubMed ID: 28400376
[TBL] [Abstract][Full Text] [Related]
15. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial.
Rubnitz JE; Crews KR; Pounds S; Yang S; Campana D; Gandhi VV; Raimondi SC; Downing JR; Razzouk BI; Pui CH; Ribeiro RC
Leukemia; 2009 Aug; 23(8):1410-6. PubMed ID: 19242495
[TBL] [Abstract][Full Text] [Related]
16. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
[No Abstract] [Full Text] [Related]
17. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.
O'Brien MM; Taub JW; Chang MN; Massey GV; Stine KC; Raimondi SC; Becton D; Ravindranath Y; Dahl GV;
J Clin Oncol; 2008 Jan; 26(3):414-20. PubMed ID: 18202418
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821.
Chang M; Raimondi SC; Ravindranath Y; Carroll AJ; Camitta B; Gresik MV; Steuber CP; Weinstein H
Leukemia; 2000 Jul; 14(7):1201-7. PubMed ID: 10914543
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]